Exploring beliefs and attitudes about genetic testing in leiomyosarcoma patients
Official title: Beliefs, Attitudes, and Response to Genetic Testing in Sarcoma Patients
Run by University of Utah · NCT06875700 · Data updated 2026-11-12
This study looks at what leiomyosarcoma patients and their families think about genetic testing and how it might affect their understanding of cancer risk.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | University of Utah Academic / other |
| Locations | 1 site (Salt Lake City, Utah) |
| Status | Recruiting |
| Started | July 9, 2024 |
| Main results expected | August 2027 |
| Study ends | August 2027 |
| Registry record updated | June 13, 2025 |
| Trial ID | NCT06875700 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 or older with leiomyosarcoma who have actionable germline pathogenic variants and have not undergone prior testing for these variants.
✕Probably not a fit
Patients under 18 years old or those who have previously undergone germline testing for the same pathogenic variant may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study investigates the beliefs and attitudes of leiomyosarcoma (LMS) patients regarding the heritability of their condition and their interest in genetic testing. It aims to assess the cognitive and emotional impacts of receiving genetic information, particularly focusing on patients who have actionable germline pathogenic variants. Additionally, the study evaluates the perspectives of family members concerning genetic testing and its implications for cancer risk. By understanding these attitudes, the research seeks to inform better integration of genetic testing into patient care.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of genetic predispositions in leiomyosarcoma patients, leading to improved screening and preventive measures for at-risk relatives.
How similar studies have gone: Previous studies have indicated a strong interest in genetic testing among cancer patients, suggesting that this approach may yield valuable insights.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion LMS Proband * Actionable germline PV detected in the research context * Living * No prior germline testing for this PV * Able to speak and read English * Mentally competent * Age 18 or older Relative of LMS Proband * 25-50% chance for having inherited the PV * No prior germline testing for this PV * Able to speak and read English * Mentally competent * Age 18 or older Exclusion (both cohorts) * \<18 years * Unable to read or write
Where it's running
-
Huntsman Cancer Institute at the University of Utah
Salt Lake City, Utah, United States Recruiting
Study contacts
- Study coordinator: Gregg Wood
- Email: gregg.wood@hci.utah.edu
- Phone: 8016464215
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
REC-617 treatment in RB1-negative leiomyosarcoma for adults who have had prior therapy
This study tests REC-617 to see if it can help control RB1-negative leiomyosarcoma in adults who have already received prior systemic treatment.
-
Methionine-Reduced Diet in Solid Tumors (early-phase)
A small pilot study will test whether a methionine-reduced diet can change blood levels in adults with various solid tumors who are receiving standard cancer therapy.
-
Ivonescimab treatment for people with leiomyosarcoma
We will try ivonescimab in adults with advanced or unresectable leiomyosarcoma to see if it controls the cancer and causes few or mild side effects.
-
Three-week preoperative proton versus X-ray radiotherapy for localized soft tissue sarcoma
This trial tests whether selecting proton rather than standard X‑ray radiotherapy before surgery for adults with localized soft tissue sarcoma can lower long-term radiation side effects without increasing surgical complications.
-
Combining STC-15 with Toripalimab for Advanced Cancers
This study is testing whether combining a new cancer drug, STC-15, with toripalimab can help people with advanced cancers feel better and improve their treatment outcomes.
-
Combining immune therapy with chemotherapy for advanced soft tissue sarcoma
This study is testing if combining a new immune therapy with standard chemotherapy can help people with advanced soft tissue sarcoma who can’t have surgery or radiation feel better and live longer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.